Brief: Casi Pharmaceuticals' Partner Juventas's New Drug Application For Cnct19 Accepted By China National Medical Products Administration
15/12/2022 14:13
Dec 15 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG
APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL
PRODUCTS ADMINISTRATION
* CASI PHARMACEUTICALS INC- HAS BEEN GRANTED ORPHAN DRUG
DESIGNATION FROM FDA AND BREAKTHROUGH DESIGNATION STATUS BY
CHINA CENTER OF DRUG EVALUATION
Source text for Eikon: ID:nPnblFnpPa
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary